- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Goldman Sachs Bets Large on Biocon Biosimilars
Biocon Biologics nets a $150 million investment from Goldman Sachs to further its development and marketing of biosimilars.
Biosimilar company Biocon Biologics said it will receive a $150 million investment from Goldman Sachs.
Biocon said in a statement that it regarded the capital infusion as a sign of confidence from the global investment community in the potential of the Bangalore, India-based company.
“This capital injection by Goldman Sachs will enable us to make prudent investments in [research and development], high-quality manufacturing, as well as establish a global commercial footprint,” said Christiane Hamacher, PhD, CEO of Biocon Biologics.
Biocon markets 2 biosimilars in the US: a trastuzumab (Ogivri) and a pegfilgrastim (Fulphila), both in partnership with Mylan. The companies have also launched an insulin glargine (Semglee), which references Lantus.
The product is essentially a biosimilar, but was not approved as one owing to the regulatory pathway followed. Biocon and Mylan are seeking biosimilar and interchangeable status for Semglee. Interchangeable status would mean pharmacists could dispense it without physician involvement.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Study: More Biosimilar Competition Is Not Lowering Patient OOP Costs
March 29th 2024Despite more biosimilars entering the market and generating significant savings for payers and health care systems, these savings are not resulting in lower out-of-pocket (OOP) costs for patients, according to a recent study.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
